CODX Stock Plunges To All-Time Lows On 1-for-30 Reverse Stock Split Approval

After the reverse split becomes effective, Co-Diagnostics will have around 2.1 million outstanding shares.
ZoomInfo said net revenue retention was stable for the third consecutive quarter.
ZoomInfo said net revenue retention was stable for the third consecutive quarter. | Photo Courtesy of Wikimedia Commons
Profile Image
Arnab Paul·Stocktwits
Updated Dec 30, 2025   |   11:26 AM EST
Share
·
Add us onAdd us on Google
  • Shareholders approved a reverse stock split range of 1-for-2 to 1-for-30 at a special meeting on December 5.
  • Split-adjusted trading will begin on the Nasdaq at market open on January 2.
  • The company’s quarterly sales have fallen short of Wall Street estimates in the past four quarters, according to Koyfin data.

Shares of Co-Diagnostics Inc. (CODX) slumped 20% to an all-time low after the company announced a 1-for-30 reverse stock split, in an attempt to regain compliance with Nasdaq’s $1.00 minimum bid price rule.

The reverse split will consolidate 30 outstanding shares into one, with adjustments made to stock options and warrants. Split-adjusted trading will begin on the Nasdaq at market open on January 2. The company noted that fractional shares will not be issued.

Earlier, shareholders approved a reverse stock split range of 1-for-2 to 1-for-30 at a special meeting on December 5, with the board ultimately choosing the 1-for-30 option. After the reverse split becomes effective, Co-Diagnostics will have around 2.1 million outstanding shares.

2025 Highlights

The company posted a weak third-quarter (Q3) print last month, with revenue falling 83% even as net loss narrowed to $5.9 million. Its quarterly sales have fallen short of Wall Street estimates in the past four quarters, according to Koyfin data.

In October, Co-Diagnostics signed an agreement with Saudi Arabia–based Arabian Eagle Manufacturing to form a joint venture called CoMira Diagnostics. The JV will develop, manufacture, and commercialize Co-Dx technologies, including its polymerase chain reaction (PCR) point-of-care platform, across Saudi Arabia and 18 other countries in the Middle East and North Africa.

On Monday, Co-Diagnostics said it had been granted a patent in Australia covering its new Co-Dx PCR platform, strengthening the company’s intellectual property portfolio. The patent provides broad protection in Australia for the design and operation of the Co-Dx PCR Pro instrument and test system.

How Did Stocktwits Users React?

Retail sentiment on Stocktwits has remained in the ‘bearish’ territory over the past 24 hours.

CODX.png

A Stocktwits user saw a "silver lining’ in the potential low float.

CODX stock has been under heavy selling pressure this year, declining more than 75%.

Read Also: VivoPower Just Announced A Deal That Could Return It To Group-Level Profitability

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share
·
Add us onAdd us on Google
Read about our editorial guidelines and ethics policy